1. [Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
- Author
-
Arutyunov GP, Lopatin YM, Ametov AS, Ageev FT, Antsiferov MB, Villevalde SV, Vinogradova NG, Galstyan GR, Galyavich AS, Gilyarevskiy SR, Glezer MG, Zhirov IV, Ilyin MV, Lebedeva AI, Nedogoda SM, Salukhov VV, Tarlovskaya EI, Tereshchenko SN, Fomin IV, Khalimov IS, Khasanov NR, Cherkashin DV, and Yakushin SS
- Subjects
- Humans, Glucosides adverse effects, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Diabetes Mellitus, Type 2 drug therapy, Heart Failure drug therapy, Cardiovascular Diseases drug therapy
- Abstract
At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.
- Published
- 2021
- Full Text
- View/download PDF